Independent Panel on Pandemic Influenza Preparedness

Independent Panel on Pandemic Influenza Preparedness
Name	Independent Panel on Pandemic Influenza Preparedness
Formation	2005
Type	Advisory panel
Purpose	Pandemic influenza preparedness review and recommendations
Location	Geneva
Leader title	Chair
Leader name	David Heymann
Affiliations	World Health Organization, United Nations

Independent Panel on Pandemic Influenza Preparedness

The Independent Panel on Pandemic Influenza Preparedness was an ad hoc international review body convened to evaluate responses to severe influenza outbreaks and to recommend improvements to global health readiness. It brought together public health experts, diplomats, and representatives from WHO member states to assess lessons from influenza events and to advise policy changes for future pandemics. The panel's work intersected with major actors in global health, multilateral institutions, and national public health agencies.

Background and Establishment

The panel was established following heightened concern after the 2003 SARS outbreak and the emergence of H5N1 avian influenza as a transnational threat, with formal creation influenced by debates at the World Health Assembly and discussions among officials from United States Department of Health and Human Services, European Commission, and the Ministry of Health (Indonesia). Its formation echoed prior inquiries such as the Commission on Human Security and drew on lessons from inquiries into the 2009 flu pandemic and the response to H1N1 influenza pandemic. Founding participants included senior figures from Global Outbreak Alert and Response Network, Centers for Disease Control and Prevention, and the Gavi, the Vaccine Alliance.

Mandate and Objectives

The panel's mandate was to review surveillance, vaccine production, antiviral stockpiling, and information sharing mechanisms across institutions like the World Health Organization, Food and Agriculture Organization, and the World Organisation for Animal Health. Objectives included evaluating legal frameworks influenced by the International Health Regulations (2005), assessing equitable access considerations highlighted by advocates such as Médecins Sans Frontières and Oxfam International, and proposing mechanisms to improve collaboration among stakeholders including Bill & Melinda Gates Foundation, Wellcome Trust, and national bodies such as the Public Health Agency of Canada.

Membership and Governance

Membership combined experts from academia, such as scholars affiliated with Harvard University, London School of Hygiene & Tropical Medicine, and Johns Hopkins Bloomberg School of Public Health, with former officials from World Health Organization regional offices, ambassadors accredited to United Nations Office at Geneva, and representatives from private sector partners like GlaxoSmithKline and Sanofi. Governance structures referenced models used by the Independent Commission on Aid Impact and incorporated advisory panels similar to those of the Global Health Security Agenda. Chairs and vice-chairs included notable public health leaders who had also served on commissions such as the Commission on a Global Health Risk Framework for the Future.

Activities and Recommendations

The panel conducted country visits to nations affected by outbreaks, convened workshops with stakeholders from Indonesia, Thailand, Vietnam, China, and Egypt, and published reports recommending reforms to vaccine production capacity, technology transfer agreements, and material sharing arrangements akin to the Pandemic Influenza Preparedness Framework. Recommendations urged strengthening laboratory networks like the European Centre for Disease Prevention and Control and expanding manufacturing commitments by entities such as Novartis. It advocated for enhanced data sharing with platforms used by ProMED-mail and collaborations with research funders including the National Institutes of Health and the European Research Council.

Impact and Influence on Policy

Findings influenced deliberations at the World Health Assembly and informed policy shifts in organizations such as the World Bank and the Asian Development Bank. Several member states adjusted national pandemic plans in line with the panel's guidance, affecting procurement strategies used by United Kingdom Department of Health and Social Care and Australian Department of Health. Recommendations contributed to revisions of the Pandemic Influenza Preparedness Framework and spurred partnerships between vaccine manufacturers and initiatives like Coalition for Epidemic Preparedness Innovations. The panel's work was cited in reports by UNICEF and International Red Cross and Red Crescent Movement.

Criticisms and Challenges

Critics raised concerns about perceived conflicts involving pharmaceutical industry participants including Pfizer and Johnson & Johnson, and questioned transparency relative to standards set by the Open Government Partnership. Some public health scholars from institutions like University of Oxford and University of Tokyo argued that recommendations favored market mechanisms over compulsory licensing approaches exemplified by debates under the Agreement on Trade-Related Aspects of Intellectual Property Rights. Operational challenges included coordination with regional bodies such as the Africa Centres for Disease Control and Prevention and securing commitments from major manufacturers headquartered in Switzerland and France.

Legacy and Succession Plans

The panel's legacy informed subsequent initiatives, feeding into successor mechanisms within the World Health Organization and into global financing proposals advanced by the G20 and the United Nations General Assembly. Elements of its agenda persisted in programs managed by CEPI and in legal reforms shaping the International Health Regulations (2005). Its recommendations influenced institutional reforms debated at forums like the Global Health Summit and laid groundwork for future review panels modeled after inquiries such as the Independent Panel for Pandemic Preparedness and Response.

Category:Public health organizations Category:Pandemics